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ABSTRACT
Carbonic anhydrase IX (CAIX) is strongly induced by hypoxia and its 
overexpression is associated with poor therapeutic outcome in cancer. Here, we report 
that hypoxia promotes tumour heterogeneity through the epigenetic regulation of 
CAIX. Based on hypoxic CAIX expression we identify and characterize two distinct 
populations of tumour cells, one that has inducible expression of CAIX and one that 
does not. The CAIX+ve population is enriched with cells expressing cancer stem 
cell markers and which have high self-renewal capacity. We show that differential 
CAIX expression is due to differences in chromatin structure. To further investigate 
the relationship between chromatin organization and hypoxic induction of CAIX 
expression we investigated the effect of JQ1 an inhibitor of BET bromodomain proteins 
and A366 a selective inhibitor of the H3K9 methyltransferase G9a/GLP. We identified 
that these drugs were able to modulate hypoxic CAIX expression induction. This 
further highlights the role of epigenetic modification in adaption to hypoxia and also 
in regulation of heterogeneity of cells within tumours. Interestingly, we identified 
that the two subpopulations show a differential sensitivity to HDAC inhibitors, NaBu 
or SAHA, with the CAIX positive showing greater sensitivity to treatment. We propose 
that drugs modulating chromatin regulation of expression may be used to reduce 
heterogeneity induced by hypoxia and could in combination have significant clinical 
consequences.
INTRODUCTION
During tumour development, rapid expansion and 
growth of cancer cells creates poorly vascularized regions, 
characterized by hypoxia, with irregular blood flow, low 
pH and nutrient starvation conditions which select for a 
more aggressive tumour phenotype [1]. 
Cellular responses and adaptation to hypoxia 
are mediated partly through stabilization of hypoxia 
inducible transcription factors (HIFs). The HIFs induce 
the transcription of many hypoxia-response genes, 
involved in angiogenesis e.g. vascular endothelial growth 
factor (VEGF), pH regulation e.g. carbonic anhydrase 
9 (CA9), and alterations in cellular metabolism e.g. 
lactate dehydrogenase-A (LDHA) by binding to hypoxia-
response elements (HRE) in their promoters [2]. CAIX 
catalyzes the reversible hydration of CO2 to bicarbonate 
and a proton. This enables tumours to maintain a more 
neutral intracellular pH (pHi) which promotes survival but 
produces a more acidic extracellular pH (pHe) [3] which 
promotes invasion and metastasis. The expression of 
CAIX is associated with poor survival in most cancers, 
[4, 5 ,6]. 
Cancer stem cells (CSC) generate cancer cell 
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heterogeneity commonly observed in clinical samples. 
However, most treatment strategies fail to address tumour 
heterogeneity sufficiently. Hypoxia is linked with stem 
cell niches. For example, the transcription factors HIF1α 
and HIF2α have been linked to the stimulation of cancer 
stem cells (CSCs) in glioblastoma [7, 8]. Wicha et al 
showed that hypoxia induced by inhibition of angiogenesis 
increases the population of breast CSCs in xenografts [9]. 
Accordingly, the poor patient survival and therapeutic 
resistance that is associated with hypoxia may be a 
result of increased proportion of CSCs in tumours [10]. 
Therefore, combination studies of currently identified 
stem cell markers with hypoxic markers may give a direct 
insight into the relationship between tumour heterogeneity 
in response to hypoxia and the role of stem cells. 
A promising hypoxic marker for such studies is 
CAIX since its expression in normal tissues is limited 
to niches that correspond to sites harboring adult stem 
cells [11]. In addition, CAIX expression is required 
for the maintenance of CSC, and plays a role in the 
invasive potential of breast cancer cells and production of 
mammospheres [12, 13]. 
In this study we demonstrate that there is marked 
heterogeneity in CAIX expression within cancer cell 
lines, in contrast to many other HIF-target genes. The 
subpopulation that selectively induces CAIX is associated 
with the regulation of stemness. Our results provide further 
support to the notion that hypoxic regions serve as stem 
cell niches, with CAIX being a key stem cell regulator. The 
intracellular heterogeneity can be suppressed by inhibitors 
of a “reader” and a “modifier” of chromatin. We propose 
that strategies targeting the hypoxic subpopulations using 
inhibitors of chromatin regulation will help to develop 
new combination therapies against hypoxia and CAIX.
RESULTS
Differential expression of CAIX under hypoxia
To determine the induction profile of CAIX we 
performed a 72 hour time course under 0.1% O2. The 
maximum expression of CAIX was at 72 hours both at 
RNA (Figure S1A) and protein level (Figure S1B and 
Figure S2). Therefore, subsequent hypoxic (0.1% O2) 
experiments were performed at 72 hours. FACS analysis 
in four cell lines, MCF-7, HCT116, SW1222 and MDA-
MD-231 showed that under hypoxic conditions (72 hours, 
0.1% O2) there were two populations, in the first 3 cell 
lines, which differentially expressed CAIX (Figure 1A). 
The percentage of CAIX positive cells ranged from 30% 
to 50% in the four cell lines tested (Figure S3A and S3B). 
Using FACS sorting both CAIX positive (CAIX+ve) 
and CAIX negative (CAIX-ve) cells were isolated from 
the hypoxia incubated MCF-7 cell line, and CAIX 
expression was confirmed by Western blotting (Figure 
1C). Importantly, HIF1α was analysed after the sorted 
populations were allowed to recover from hypoxia for 
1 week, then re-exposed to 0.1% O2 for 24 hours. Both 
populations produced the same levels of HIF1α but 
CAIX remained differentially expressed (Figure 1B). 
Moreover, under hypoxia in both populations only CAIX 
had differential expression compared to the well-validated 
hypoxia regulated genes LDHA, pyruvate dehydrogenase 
kinase 1 (PDK1) and adenylate kinase 4 (AK4) (Figure 
1B, 1C). 
Only the CAIX+ve population of the MCF-
7 sorted cells has the ability to recapitulate the 
original expression pattern
We then performed two rounds of sorting of 
hypoxia-induced MCF-7 cells into CAIX+ve and 
CAIX-ve populations. After 3 weeks in culture both 
cell populations were reexamined for CAIX expression 
using FACS analysis. The CAIX+ve population had 
recapitulated the original unsorted phenotype, generating 
both populations of CAIX+ve and CAIX-ve cells. The 
CAIX-ve cells were not capable of reforming both 
populations and they remained mainly negative for CAIX, 
showing only a very low levels of CAIX expression 
(Figure S4A). In order to further enrich for CAIX+ve cells 
and CAIX-ve cells, a second round of FACS sorting was 
performed. The extreme high 10% of CAIX positive cells 
and the extreme low 10% of CAIX negative cells were 
sorted and cultured in normoxic conditions for six months. 
During long-term culture (6 months), the CAIX+ve cells 
became heterogeneous, containing both CAIX+ve and 
CAIX-ve populations when exposed to hypoxia, and thus 
recapitulated the original unsorted expression pattern, 
whereas the CAIX-ve cells continued to be homogenous, 
and negative for CAIX expression after exposure of the 
cells to 0.1% O2 hypoxia (Figure 2A). Thus we generated 
CAIX+ve and CAIX-ve cell lines. We verified the CAIX 
expression status in these at both, mRNA and protein 
levels (Figure 2B, 2C).
Molecular signature of the MCF-7 CAIX positive 
and negative populations 
In order to identify genes and pathways differentially 
expressed between CAIX+ve and CAIX-ve cells, RNA 
sequencing was performed. Cells were treated with 
hypoxia (0.1% O2) for 72 hours then stained for CAIX 
expression followed by cell sorting and RNA extraction. 
2093 genes showed a greater than 2 fold up-regulation in 
the CAIX-ve population and 2670 showed a greater than 2 
fold up-regulation in the CAIX+ve population. Comparing 
the gene expression pattern of these two populations under 
hypoxia, and the unsorted population under hypoxia with 
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Figure 1: Hypoxic subpopulations of CAIX expression. Two distinct subpopulations of CAIX-ve and CAIX+ve cells in MCF-7, 
MDA-MB-231, HCT116 and SW1222 lines stained with CAIX antibody and analysed by FACS A.. CAIX+ve and CAIX-ve sorted MCF-7 
cells have the same protein levels of expression of HIF-1α, LDHA, PDK1 B. and C. and the same RNA levels of expression of HIF-1α, 
LDHA, PDK1 and AK4 D.. Error bars represent the mean ± SD. ***p < 0.001, n = 3.
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a breast cancer hypoxia expression signature [14] showed 
a similar core hypoxia response, with no difference in 
expression of well established hypoxia genes (Figure 3A). 
Interestingly, CAIX was the only hypoxia inducible gene 
distinguishing these two populations. Furthermore, the 
non-hypoxia regulated expression pattern of the CAIX+ve 
population was significantly different from both the CAIX-
ve and unsorted cells (Figure 3B). Strikingly, KEGG 
pathway analysis showed that the differential CAIX+ve 
signature was significantly enriched for pathways involved 
in stem cell maintenance, such as the ABC transporters, 
Wnt and Hedgehog signaling, tumour invasion and 
metastasis (Table 1). In contrast, the CAIX-ve signature 
was enriched for cytokine-cytokine receptor interaction, 
MAPK signaling pathway, osteoblast differentiation and 
ECM-receptor interaction pathway (Table 2). 
The CAIX+ve cells are enriched with cells 
expressing stem cell markers 
Several of the stem cell related genes were validated 
by Q-PCR and were differentially expressed in the MCF-7 
CAIX+ve sorted cells. We found that in CAIX+ve cells 
expression of ALDH1 (p < 0.001, n = 3), WNT2 (p < 0.01, 
n = 3), TWIST1 (p < 0.001, n = 3), LIN28 (p < 0.001, 
n = 3), ABCC2 (p < 0.01, n = 3), IGF1 (p < 0.001, n = 
3), SOX2 (p < 0.05, n = 3), was significantly upregulated 
(Figure 4A). CAIX silencing in the CAIX+ve cell line 
led to reduced gene expression of ALDH1 (p < 0.05, n 
= 3), TWIST1 (p < 0.05, n = 3), and ABCC2 (p < 0.001, 
n = 3), WNT2 (p < 0.01, n = 3), LIN28 (p < 0.01, n = 3), 
but it did not effect the expression of SOX2 (Figure 4B), 
showing that CAIX is involved as a mechanism as well 
as a marker. In addition, the protein expression levels of 
ALDH1 in the CAIX+ve cells sorted from two different 
cells lines, MCF7 and HCT116 were also higher compared 
to the CAIX-ve cells (Figure S4B). 
The CAIX+ve cells are enriched for stem cell like 
properties compared to CAIX-ve cells
We showed that only CAIX+ve cells possess the 
capacity to drive the original heterogeneous phenotype, a 
characteristic property of stemness [15, 16]. Importantly, 
the MCF-7 CAIX+ve cell line had significantly higher 
ALDH enzymatic activity (p < 0.01, n = 3) compared to 
the MCF-7 CAIX-ve cell line (Figure 5A) as analysed 
by the ALDEFLUOR assay. This is consistent with our 
hypothesis as high ALDH activity is associated with 
the self-renewal capacity and ability to recapitulate the 
heterogeneity of the parental tumour [17]. Interestingly, 
basal-like breast cancers, which are associated with stem 
cell phenotypes and high ALDH1 expression also show 
high CAIX expression [17, 18]. Moreover, our notion 
that the CAIX+ve population is enriched with stem-like 
cells is further supported by the fact that these cell has 
the capacity to form significantly more second-generation 
mammospheres compared to the CAIX-ve cell line (Figure 
5B, p < 0.05, n = 3), a property known to be associated 
with mammary stem/progenitor cells [13]. Interestingly, 
there is no change in cell viability under normoxic or 
hypoxic conditions between CAIX+ve and CAIX-ve cells 
(Figure S5). 
Table 1:KEGG analysis for CAIX+ve cells
Genes Hyp* Annotations
10 0.0009 ABC transporters
8 0.0392 Wnt and Hedgehog signaling pathway
14 0.0013 Dilated cardiomyopathy/tumour migration
12 0.0021
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC)/ Tumour 
EMT
11 0.0088 Protein digestion and absorption/ECM components
16 0.0058 Cell adhesion molecules (CAMs)
12 0.0061 Hematopoetic cell lineage
15 0.0057 Glutamatergic synapse
35 <0.0001 Neuroactive ligand-receptor
(Hyp* = Corrected hypergeometric pValue)
Table 2: KEGG analysis for CAIX-ve cells
Genes Hyp* Annotations
15 0.0007 Cytokine-cytokine receptor interaction
13 0.0072 MAPK signaling pathway
8 0.0203 Osteoclast differentiation
6 0.0341 ECM-receptor interaction
6 0.0376 TGF-beta signaling pathway
Oncotarget19417www.impactjournals.com/oncotarget
Figure 2: Long-term culture of CAIX+ve and CAIX-ve cells. FACS analysis of CAIX shows that only the CAIX+ve population 
has the ability to recapitulate the original expression pattern and to reform both populations in long term (6 months) culture A.. The 
expression levels of CAIX in the long term (6 months) cultures of the sorted cells was confirmed both at RNA B. and protein level C.. Error 
bars represent the mean ± SD. ** = p < 0.01, n = 3.
Figure 3: CAIX-positive and negative populations show similar hypoxia transcriptional response. A. Expression of known 
hypoxia regulated genes, B. genes over-expressed in the CAIX positive population are shown in the three experimental conditions: 1) 
whole-population (left column), 2) CAIX+ve population (middle column) and 3) CAIX-ve population (right column) exposed to hypoxia 
normalized to the normoxia whole-population control. Bar legend shows the log2 count ratio between hypoxia and the normoxia.
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Figure 4: The CAIX+ve subpopulation is enriched with cells expressing stem cell genes. A. Q-PCR analysis of genes 
implicated in stem cell maintenance in CAIX+ve and CAIX-ve populations in MCF-7 cells. B. Q-PCR analysis of genes implicated in stem 
cell maintenance in CAIX+ve cells transfected with Scr RNAi or CAIX RNAi. Error bars represent the mean ± SD. ***p < 0.001, **p < 
0.01, *p < 0.05, n = 3.
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CAIX expression promotes tumour growth in 
NSG mice
We selected the SW1222 colon cancer cells 
instead of MCF-7 breast cancer for our in vivo studies 
in order to avoid the potential confounding effects of 
estrogen supplementation. SW1222 has been previously 
utilized successfully to model differential stem cell 
phenotypes in this way previously [10] and has two 
clear CAIX subpopulations (Figure 1A). These cells 
differentially express the hypoxic marker CAIX (Figure 
1A). Importantly, only the SW1222 CAIX+ve population 
expresses the CD44+CD24+ stem cell markers [10] 
(Figure S6). The SW1222 CAIX+ve cells formed tumours 
significantly faster (p < 0.05, n = 5) than the CAIX-ve 
population, when implanted at 1000 cells (Figure 6A) and 
with 200 cells (Figure 6B). 
Although in vivo the role of CAIX in regulating pH 
may affect the gene expression patterns, in vivo analysis 
of effects of CAIX knockdown was conducted to assess if 
there was concordance of these in vitro observations. To 
this end, we produced a CAIX knockdown MDA-MB-468 
(breast cancer) cell line using stable shRNA. The CAIX 
knockdown significantly reduced xenograft growth rate (p 
< 0.05, n = 5), (Figure 6C). Gene ontology analysis of 
genes revealed that genes associated with stemness were 
more highly expressed in the CAIX expressing xenografts 
of MDA-MB-468 compared to the knockdown (Table S1). 
Q-PCR analysis confirmed significantly higher expression 
of stem cell associated gene such as: TWIST1 (p < 0.05, 
n = 4), JAG2 (p < 0.05, n = 4), OCT4 (p < 0.05, n = 4) 
and NANOG (p < 0.05, n = 4) (Figure 6D) in the CAIX 
expressing xenografts of MDA-MB-468 compared to the 
knockdown. The genes tested are stem cell marker genes. 
There may be some differences in the relative expression 
and dependence on stem cell related genes in different 
systems i.e MCF-7 (ER positive breast cancer cell line) 
Figure 5: The CAIX+ve subpopulation has functional properties associated with cancer stem cells in vitro and in vivo. 
A. Representative FACS analysis of MCF-7 CAIX+ve and CAIX-ve cell lines for ALDH activity (ALDEFLUOR kit) B. The number of 
mammospheres per microscopic field was determined. Data are shown as the number of mammospheres per field performed in triplicates. 
Error bars represent the mean ± SD. ***p < 0.001, *p < 0.05, n = 3.
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versus MDA-MB-468 (triple receptor negative breast 
cancer). In addition to this, previous studies have shown 
that CAIX is upregulated in basal-like breast tumours 
[19], which are characterized by their stem like phenotype 
[20]. Given the above and the fact that MDA-MB-231 and 
MDA-MB-468 are basal-like breast cancer cell lines, we 
postulate that the more uniform expression of CAIX in 
these cell lines is due to the higher proportion of stem like 
cells in these cell lines (Figure S7).
Epigenetic regulation of the CA9 genomic locus
We hypothesized that differences in chromatin 
organization were a likely mechanism for CAIX 
differential regulation. Using the Epiq chromatin 
analysis kit the chromatin state of a given locus could be 
interrogated on the basis of its accessibility to nuclease 
digestion. The MCF-7 CAIX-ve cells displayed a more 
“closed” chromatin state as shown by the low accessibility 
to nuclease digestion, which correlates with low mRNA 
expression of CA9 (Figure 7A). In contrast, the MCF-7 
CAIX+ve cells under hypoxia adopted a more “open” and 
accessible chromatin state around CA9 promoter region, 
which is associated with high expression of CA9 (Figure 
7A). Interestingly both populations under normoxic 
condition have a compact “silenced” chromatin. 
To verify this data we performed chromatin 
immunoprecipitation (ChIP) on MCF-7 CAIX+ve 
and CAIX-ve cell lines to evaluate the levels of the 
tri-methyl H3K9 histone, a well-validated marker of 
heterochromatin. Under hypoxic conditions the MCF-
7 CAIX-ve cell line had significantly (p < 0.05, n = 3) 
higher levels of tri-methyl H3K9 histone compared to 
the MCF-7 CAIX+ve cell line, confirming the nuclease 
Figure 6: Analysis of CAIX positive and CAIX negative cell lines on ability to promote tumour growth in vivo. CAIX+ve 
and CAIX-ve cells derived from SW1222 cells were implanted at 1000 A. or 200 cells B. and growth monitored over time. C. CAIX 
knockdown reduced the growth rate of MDA-MB-468 xenografts. D. Q-PCR analysis of stem cells genes in shMDA-MB-468 and Empty 
Vector (EV) xenografts. Error bars represent the mean ± SD, *p < 0.05, n = 3.
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digestion assay (Figure 7B). Given that HIF induces the 
transcription of CA9 by binding to HRE in its promoters 
we hypothesized that this interaction should be reduced 
in our CAIX-ve cells. A significant (p < 0.05, n = 3) 
reduction in binding of HIF1α  to the CA9 promoter of 
the negative population was identified as determined by 
ChIP (Figure 7C). In addition, MCF-7 CAIX+ve and 
CAIX-ve cell lines were treated with A366 a selective 
inhibitor of the H3K9 methyltransferase G9a/GLP. A366 
treatment under hypoxic conditions significantly increased 
the level of CAIX expression in both MCF-7 CAIX+ve 
and CAIX-ve cells as analysed by FACS (CAIX+ve p < 
0.01, n = 3; CAIX-ve p = 0.01, n = 3)(Figure S8A and B), 
and western blot (Figure S8C). The drug treatment impacts 
on chromatin in both populations leading to the change 
in CAIX expression, which may indicate that the effect 
of A366 could be indirect. A366 did not affect HIF1α 
stabilization (Figure S8C) levels of an alternative HIF 
target gene LDHA.
Further to this MCF-7 CAIX+ve and CAIX-ve 
cell lines were treated with a selective inhibitor of the 
bromodomain family JQ1. JQ1 significantly reduced 
CAIX expression (CAIX+ve p < 0.05, n = 3; CAIX-ve 
p = 0.05, n = 3) (Figure 7D), but did not affect HIF1α 
stabilization or LDHA expression (Figure 7E). 
Figure 7: Hypoxic induction of CAIX expression is regulated by chromatin accessibility. A. Semi-quantitative analysis of 
chromatin compaction within CA9 genomic locus in CAIX+ve and CAIX-ve cells under normoxic and hypoxic conditions using EpiQ 
assay ploted againist relative mRNA expression of CA9. B. Levels of tri-methyl H3K9 histone at the CA9 promoter region in CAIX positive 
and negative cell lines, in normoxia and hypoxia. C. Binding of HIF-1β to the CA9 promoter region in CAIX positive and negative cell 
lines. D. and E. JQ1 decreases CAIX expression in CAIX+ve and CAIX-ve cells as analysed by FACS and western blot. HIF1α and LDHA 
proteins levels E. in JQ1 treated CAIX+ve and CAIX-ve cells. Error bars represent the mean ± SD. ***p < 0.001, **p < 0.01, *p < 0.05, 
n = 3.
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HDAC inhibitors target the cells expressing CAIX 
Previous studies have shown that HDAC inhibitors 
(NaBu and SAHA) induce early differentiation in 
embryonic stem cells, by reducing the expression of key 
regulatory stem cell genes such as SOX2, NANOG, and 
OCT4 [10, 21, 22]. Given the above we tested the effect 
of NaBu treatment on CAIX expression. We observed that 
NaBu treatment caused a significant downregulation of 
CAIX (p < 0.01, n = 3) expression and the expression of 
the colon cancer stem cell marker CD133 (p < 0.05, n = 
3) (Figure S9).
In order to verify this result we also investigated 
the effect of SAHA, in the MCF-7 breast cancer cell 
line. SAHA treatment significantly downregulated the 
expression of CAIX (p < 0.05, n = 3) and the expression 
of the breast cancer stem cell marker CD44 (p < 0.05, 
n = 3) (Figure 8A). The expression of HIF1α was not 
downregulated upon SAHA treatment, but the two 
validated HIF and hypoxia regulated genes PDK1 (44% 
reduction) and AK4 (80%) were, although to a lesser 
extent than CAIX (95%) (Figure 8B). 
Next we investigated whether SAHA induced CAIX 
downregulation specifically targets MCF-7 CAIX+ve cells 
by affecting their survival. SAHA treatment significantly 
(p < 0.05, n = 3) reduced the number of colonies of the 
MCF-7 CAIX+ve cell line (Figure 8C) compared to the 
colonies of the MCF-7 CAIX-ve cell line. Additionally, we 
evaluated the CAIX expression in untreated and SAHA-
treated colonies of the MCF-7 CAIX+ve cell line after 
the 10d recovery. The expression of CAIX in the SAHA 
treated colonies was significantly (p < 0.05, n = 3) reduced 
compared to the untreated colonies (Figure S10). 
To understand if the sensitivity of CAIX+ve cells to 
SAHA was dependent on the CAIX status we transfected 
the MCF-7 CAIX+ve population with CAIX RNAi or Scr 
RNAi and then treated with SAHA for 72 hours under 
hypoxic conditions. After 72hours SAHA was removed 
from the medium, then cells were allowed to recover 
for another 24hours under normoxia and the cell growth 
was assessed by cell counting. Treatment with SAHA 
significantly reduced cell growth of the cells transfected 
with Scr RNAi (p < 0.05, n = 3) compared to the MCF-7 
CAIX knockdown cells (Figure 8D). Moreover, growth 
of the MCF-7 CAIX+ve cell line (p < 0.01,n = 3) was 
also reduced as compared to the MCF-7 CAIX-ve cell 
line (Figure 8D). These results suggest that expression of 
CAIX confers sensitivity to SAHA treatment in the MCF-
Figure 8: Effects of SAHA treatment on CAIX+ve and CAIX-ve populations. A. FACS analysis for CAIX and CD44 in 
hypoxia in SAHA treated and untreated MCF-7. B. Protein levels of HIF-1α, CAIX, PDK1 and AK4 in SAHA treated and untreated MCF-
7 cells. C. Clonogenic survival assay for MCF7 CAIX+ve and CAIX-ve cell lines treated with SAHA. D. Effects of SAHA treatment on 
cell growth of MCF7 CAIX+ve, MCF7 CAIX-ve and MCF7 CAIX knockdown cells. Error bars represent the mean ± SD. **p < 0.01, *p 
< 0.05, n = 3.
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7 CAIX+ve population. Given the above it is likely that 
CAIX could be a valuable biomarker in treatment utilizing 
HDAC inhibitors. 
DISCUSSION
Solid tumours, including breast cancer, are 
composed of heterogeneous cell populations that interact 
in complex networks. CAIX heterogeneity is associated 
with disparities of many stem cell genes. Previous 
studies have shown that CAIX expression is associated 
with stem cell niches in normal tissues [11], and plays a 
crucial role in the invasive potential of breast cancer cells 
and mammospheres [12, 13]. Here we demonstrate that 
the CAIX+ve gene signature was significantly enriched 
for pathways and genes which have been shown to play 
an important role in the recurrence and maintenance of 
cancer stem cells [23], [24]. Accordingly, we also show 
that only CAIX+ve cells possess the capacity to drive the 
original heterogeneous phenotype, consisting of CAIX-ve 
and CAIX+ve cells in long-term culture, a characteristic 
measurement of stemness [15, 16]. Interestingly, our data 
show that suppression of CAIX in vitro and in vivo causes 
a significant downregulation of breast cancer stem cell 
signatures. This suggest that CAIX does not serve only as 
a marker for the enrichment of hypoxic cancer stem cells, 
but its expression induces some stem cell phenotypes. 
Inhibition of the carbonic anhydrase activity of CAIX 
has been previously shown to deplete cancer stem cells 
in tumours [12] in vivo suggesting that it is the ability 
of CAIX to regulate pH that is key for stem cells. It is 
unlikely that all CAIX+ve cells are stem cells per se or 
that CAIX-ve cells have no stem cells. Nevertheless, 
it is intriguing that the CAIX induction program is so 
strongly associated with genes commonly expressed in 
stem cells. One possibility is that this creates an extensive 
microenvironment of regulated pH around the fewer stem 
cells, a syncytial pH rim, as we showed previously in 
spheroid models of CAIX expression [25].
We would suggest a term for this population, the 
hypoxia induced ‘stem cell pH buffer zone’ producing 
a pH-protected zone enriched for stem cell populations, 
but having properties conducive to protect them from 
environmental stress.
Alterations in global levels of specific modifications, 
such as methylation or acetylation generate an additional 
layer of epigenetic heterogeneity at the cellular level in 
tumour tissues. Here we demonstrated that the molecular 
mechanism underlying the differential expression of CAIX 
is due to hypoxia induced reorganization of chromatin 
structure. The CAIX-ve cells have a relatively “closed” 
and transcriptionally silent CAIX promoter region 
under hypoxia compared to a transcriptionally active 
and “open” configuration in the CAIX+ve population. 
We investigated the relationship between chromatin 
organization and hypoxic induction of CAIX expression 
using pharmacological inhibitors of chromatin modulators. 
Given the higher levels of H3K9 methylation in the 
CAIX promoter of the negative cells, we considered that 
inhibition of the H3K9 methylation might induce CAIX 
in this population. For this reason, we used a selective 
inhibitor of the H3K9 methyltransferase G9a/GLP 
(A366). In agreement with our hypothesis, treatment 
with A366 resulted in induction of CAIX expression in 
the CAIX-ve population. We also tested the effect of 
inhibiting a chromatin modification reader, which reads 
ξ-N-acetylation of lysines, by treatment with JQ1. JQ1 
disrupts the binding of BET bromodomains to acetyl 
lysines in the chromatin, a crucial event for the recruitment 
of transcription factors necessary for gene activation. 
In line with this, JQ1 treatment significantly reduced 
CAIX expression. This highlights the role of epigenetic 
modification in adaption to hypoxia and also in regulation 
of heterogeneity of cells within tumours. Drugs targeting 
chromatin modifiers influence CAIX levels and as such 
may be used to reduce or target intra-tumour heterogeneity 
and synergize with anti-VEGF therapy.
In conclusion, using CAIX as a hypoxic marker we 
have identified for the first time a marked heterogeneity 
in response to hypoxia within three tumour cell lines, 
associated with major biological differences. We also 
identified that NaBu and SAHA treatment lead to 
elimination of the CAIX+ve population as well as a 
significant reduction in the expression of the stem cells 
associated genes CD44 and CD133. Consistent with this, 
treatment of HT29 and CaCo2 colon cancer cell lines 
with NaBu also causes a reduction in the expression of 
CD133 and CD44 [26]. Additionally, it has been shown 
that HDAC inhibitors induce early differentiation in 
embryonic stem cells (ES), by reducing the expression of 
key regulatory stem cell genes such as SOX2, NANOG, 
and OCT4 [21, 22]. The differential sensitivity to 
HDAC inhibitors may explain the relatively poor results 
with this drug class in solid tumours, and suggests that 
combinations targeting different hypoxic populations 
should be investigated. The epigenetic mechanism that 
drives the consistent induction of these two populations 
implies a key differential hypoxia program that is 
important for survival of a subpopulation of stem cells 
in a pH buffer zone. We propose that strategies targeting 
intra-tumoural heterogeneity using inhibitors of chromatin 
regulation of heterogeneous expression, including the 





Cells were maintained in a humidified incubator 
at 5% CO2 and 37ºC. 5%. All cell lines were maintained 
in DMEM supplemented with 10% FBS. Hypoxic 
incubations (0.1% O2, 5% CO2,) were performed using an 
INVIVO2 400 hypoxic workstation (Pro-Lab Diagnostics). 
Cells were treated with SAHA (Sigma) at 2 µM, NaBu 
(Sigma) at 5 mM, JQ-1 at 200 nM. A366 and JQ-1 were 
a gift from Dr Susanne Muller-Knapp (Target Discovery 
Institute, University of Oxford, UK). Spheroids were 
generated following the method described in [27].
Flow cytometry 
Flow cytometry was carried out as previously 
described [28]. Samples were analyzed using a 
DakoCytomation Cyan machine, or sorted using a 
MoFlo cell sorter (Beckman Coulter). The bottom 10% 
of CAIX negative subpopulation and the top 10% of 
CAIX positive subpopulation were collected for further 
experiments. The following primary antibodies were used 
FITC conjugated CAIX (R&D systems), APC conjugated 
CD133 (Miltenyi Biotec), APC conjugated CD44 antibody 
(BD Biosciences) and PE conjugated CD24 antibody (BD 
Biosciences). 
Chromatin analysis
The quantitative assessment of chromatin states of 
CAIX+ve and CAIX-ve cells was performed using the 
EpiQ Chromatin analysis kit according to manufacturer’s 
instructions (BioRad). Briefly CAIX+ve cell line and 
CAIX-ve cell line were plated in 48 well culture plate to 
80-95% confluent and exposed for 72hrs in 0.1% O2 or 
they were maintained under normoxic conditions. Three 
wells remained undigested and the other 3 wells were 
digested with DNase nuclease I for 1 hour. Following 
extraction and purification of the genomic DNA. The 
nuclease sensitivity was assessed by qPCR (with primers 
as shown in Table S6). The data were analysed using EpiQ 
Chromatin Kit Data Analysis Tool (www.bio-rad.com/
epiq) The GAPDH region was used as a positive reference 
gene region for an open chromatin. 
Chromatin immunoprecipitation assay
Immunoprecipitation assays for HIF-1α were 
performed using the Upstate EZ ChIP Kit Reagents 
and chromatin immunoprecipitation (ChIP) assay for 
trimethylated H3K9 was done using the EpiQuik Tri-
Methyl-Histone H3K9 ChIP Kit (Epigentek, Brooklyn, 
NY) according to manufacturer’s instructions.
Aldefluor assay
To detect ALDH activity in cells, we used the 
ALDEFLUOR kit from Stem Cell Technologies, according 
to manufacturer’s instructions.
Generation of mammospheres
MCF-7 cells were detached, washed and plated 
in a 6 well low attachment plates (Corning), filled with 
3mL MammoCult Basal Medium and supplemented with 
MammoCult proliferation Supplements, 4 µg/mL Heparin, 
0.48 µg/mL Hydrocortisol and penicillin (100 U/mL), 
streptomycin (100mg/mL). MCF-7 mammospheres were 
started forming after day 4-6 and were processed at day 
10. Secondary generation mammospheres were generated 
by incubating the primary mammospheres with 1 X 
Trypsin EDTA solution (PAA Laboratories) for 2-3 min 
and resuspended in the above medium and plated again 
in the low attachment plates. After 7 days the capacity of 
cells to generate secondary mammospheres were tested 
by visualizing the cells with the inverted light microscope 
(Axiovert). 
Production of stable CAIX knockdown MDA-
MB-468 cells
To knockdown CA9 in MDA-MB-468, the HuSH-
29 shRNA targeting CA9 (TR314250) and empty vector 
(R20003) were purchased from Origene. The shCA9 
sequence was cloned into pcDNA3.1. Cell lines were 
transfected with FuGENE 6 (Roche) according to 
manufacturer’s instructions. Cell line pools were grown 
under selective pressure [0.4 mg/mL G418 (Invitrogen)] 
until no mock-transfected cells remained. 
Immunoblotting
Cell lysates were separated on 10% SDS-PAGE 
and transferred to polyvinylidene difluoride membrane. 
Primary antibodies were used at 1:1,000 unless otherwise 
stated. The following antibodies were used, mouse anti-
HIF1α, (BD Transduction Laboratories, USA), mouse 
anti-CAIX (Gift form J. Pastrorek, Institute of Virology, 
Slovak Republic), goat anti-LDHA (Santa-Cruz), goat 
anti-PDK1 (Santa-Cruz), goat anti-AK4 (Santa-Cruz), 
mouse anti-ALDH (BD Biosciences), mouse anti-β actin 
(Sigma). Blots were quantified with image analysis in 
ImageJ. 
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Real-time PCR (Q-PCR) 
RNA extraction and the quantitative PCR protocol 
have been described previously (33). The sequences of the 
primers used are showing in Table S2.
RNA-sequencing and gene expression array 
analysis 
RNA was extracted as described above. The RNA-
seq was performed according to the sample preparation 
guide (Illumina, TruSeq RNA). TopHat [29] was used to 
align RNA-Seq reads to the human genome build 37.1. 
Bedtools [30] was used to summarize the number of reads 
per exon per transcript. Threshold for transcript presence 
was set to 15 reads. Samples were then normalized using 
the total number of mapped reads. The logarithm base 2 
of the ratio of counts between conditions was estimated 
and a filter was applied to select genes with an absolute 
logarithm greater than 1; this is equivalent to one fold 
change up- or down-regulation between conditions. 
Enrichment for KEGG pathways (http://www.
genome.jp/kegg/) was performed using Genecodis 2.0 
[31, 32]; Ensembl IDs (GRCh37 assembly) were used 
as reference, hypergeometric test was used and false 
discovery rate threshold was set to 0.05.
For Illumina expression. Briefly, RNA concentration 
was normalized to 50ng/ul of which 11ul used to produce 
biotin-labelled complementary RNA (cRNA) using 
Illumina TotalPrep-96 RNA amplification kit from 
Ambion #4393543. 750ng of biotin-labelled cRNA 
from each sample was hybridized according to Illumina 
whole-genome gene expression direct hybridization 
assay from Illumina #11286340 to high-density Illumina 
Human oligonucleotide arrays Human HT-12_V4_0_
R1_15002873_B; designed to detect 47,231 transcripts. 
The Fluorescence emissions were quantitatively detected 
using iScanner and data were extracted using BeadStudio 
v20111.1 Software (Illumina Inc) which were imported 
to GeneSpring GX 12.1 (Agilent Technologies, Inc., 
Santa Clara, CA) ; normalized with Shift to 75 percentile 
and baseline transformed to median of all samples to 
identify significantly differentially expressed genes with 
FDR (Benjamini-Hochberg) corrected P-value cut off at 
< 0.01. Functional and pathway analysis carried out on 
differentially expressed genes to identify statistically 
over-represented ontologies in the list using Database 
for Annotation, Visualization and Integrated Discovery 
(DAVID; Huang da et al., 2009b; Huang da et al., 2009a).
Xenograft studies
Mice were housed at BMS, University of Oxford, 
UK, and procedures were carried out under a Home 
Office licence. SW1222 cells were exposed in hypoxia 
for 72h and then were sorted in CAIX+ve and CAIX-ve 
population. 1000 CAIX+ve, CAIX-ve and 200 CAIX+ve, 
CAIX-ve cells were inoculated in six to seven-week old 
male NSG mice subcutaneously in the lower flank with 
100μL Matrigel (BD Bioscience). MDA-MB-468 EV and 
shCA9 cells were inoculated in six to seven-week old 
female BALB/c NuNu mice subcutaneously in the lower 
flank with 1x107 with 50μL Matrigel (BD Bioscience). 
Tumour growth was monitored three times per week 
measuring the length (L), width (W) and height (H) of 
each tumour using calipers. Volumes were calculated 
from the formula 1/6 x π x L x W x H. When tumours 
reached 1.44 cm3 the mice were sacrificed by cervical 
dislocation. Ninety minutes prior to sacrifice, mice 
were injected intravenously with 2 mg of pimonidazole 
(Hypoxyprobe-1; Chemicon International, USA) as 
described previously [33].
Gene silencing by RNA interference
Transfections of siRNA duplexes targeting CAIX or 
a scramble control (scr) (ON-TARGETplus SMARTpool) 
at a final concentration of 20 nM, were performed in 
Optimem (Invitrogen), using Oligofectamine reagent 
(Invitrogen). The sequences of siRNA used to target CAIX 
were 118898, 9567 and 9473 (Invitrogen). 
Clonogenic assay
CAIX+ve and CAIX-ve cells were seeded at 
a density of 1000 cells per 6 cm dish in triplicates 
and treated with 2 µM SAHA for 72h under hypoxic 
conditions, untreated control cells were also included in 
the experiment. After 72h the dishes incubated in hypoxia 
were returned to normoxia for 10 days and allowed to 
form colonies. Cell colonies were fixed and stained with 
Methylene blue for 1 hour. Visible colonies were counted 
using a ColCount automated colony counter (Optronix). 
Statistical analyses
Statistical analysis and graphs were performed using 
GraphPad Prism® v4.0 software (GraphPad). Statistics 
were carried out using non-paired Student’s t-tests and 
significance is represented by *p < 0.05, **p < 0.01, 
and ***p < 0.001. Error bars represent mean ± Standard 
Deviation (SD). 
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